Ontology highlight
ABSTRACT:
SUBMITTER: Kaufman JL
PROVIDER: S-EPMC7986778 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
Kaufman Jonathan L JL Gasparetto Cristina C Schjesvold Fredrik H FH Moreau Philippe P Touzeau Cyrille C Facon Thierry T Boise Lawrence H LH Jiang Yanwen Y Yang Xiaoqing X Dunbar Fengjiao F Vishwamitra Deeksha D Unger Stefanie S Macartney Tammy T Pesko John J Yu Yao Y Salem Ahmed Hamed AH Ross Jeremy A JA Hong Wan-Jen WJ Maciag Paulo C PC Pauff James M JM Kumar Shaji S
American journal of hematology 20210119 4
Venetoclax (Ven) is a selective small-molecule inhibitor of BCL-2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) combination in patients with t(11;14) positive relapsed/refractory (R/R) multiple myeloma (MM). This open-label, multicenter study had two distinct phases (phase one [P1], phase two [P2]). Patients in both phases received VenDex (oral Ven 800 mg/day + oral Dex 40 mg [20 mg for pati ...[more]